Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast - Female|Male Breast Cancer
Interventions: DRUG: Pembrolizumab|DRUG: Paclitaxel
Sponsor: Wake Forest University Health Sciences
Collaborators: Merck Sharp & Dohme LLC